GALECTO INC (GLTO) Stock Price, Quote, News and Overview
NASDAQ:GLTO - Nasdaq - US36322Q2066 - Common Stock - Currency: USD
GLTO Quote, Performance and Key Statistics
2.79
+0.02 (+0.72%)
The current stock price of GLTO is 2.79 USD. In the past month the price increased by 12.05%. In the past year, price decreased by -82.03%.
GLTO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.57B | ||
| AMGN | AMGEN INC | 13.03 | 145.41B | ||
| GILD | GILEAD SCIENCES INC | 13.1 | 126.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.96 | 61.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.71B | ||
| ARGX | ARGENX SE - ADR | 92.41 | 33.12B | ||
| ONC | BEIGENE LTD-ADR | 5.58 | 24.22B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.72B | ||
| NTRA | NATERA INC | N/A | 20.70B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.28B | ||
| BIIB | BIOGEN INC | 7.79 | 18.05B |
Related stock screener links
About GLTO
Company Profile
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2020-10-29. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. The company is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Company Info
GALECTO INC
75 State Street, Suite 100
Boston MASSACHUSETTS DK-2200 US
CEO: Hans T. Schambye
Employees: 13
Phone: 14570705210
GALECTO INC / GLTO FAQ
What is the stock price of GALECTO INC today?
The current stock price of GLTO is 2.79 USD. The price increased by 0.72% in the last trading session.
What is the ticker symbol for GALECTO INC stock?
The exchange symbol of GALECTO INC is GLTO and it is listed on the Nasdaq exchange.
On which exchange is GLTO stock listed?
GLTO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GALECTO INC stock?
8 analysts have analysed GLTO and the average price target is 8.16 USD. This implies a price increase of 192.47% is expected in the next year compared to the current price of 2.79. Check the GALECTO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GALECTO INC worth?
GALECTO INC (GLTO) has a market capitalization of 3.68M USD. This makes GLTO a Nano Cap stock.
How many employees does GALECTO INC have?
GALECTO INC (GLTO) currently has 13 employees.
What are the support and resistance levels for GALECTO INC (GLTO) stock?
GALECTO INC (GLTO) has a support level at 2.75 and a resistance level at 2.81. Check the full technical report for a detailed analysis of GLTO support and resistance levels.
Should I buy GALECTO INC (GLTO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GLTO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GLTO, evaluating the profitability, health, valuation and growth aspects
- GALECTO INC (GLTO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GALECTO INC (GLTO) Sales and EPS estimates to see what analysts future expectations are.
- GALECTO INC (GLTO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GALECTO INC (GLTO) Insider and Institutional Ownership to learn about the owners and their transactions.
- GALECTO INC (GLTO) Stock Chart to make your own analysis
- GALECTO INC (GLTO) Latest news and press-releases to stay up to date.
Does GALECTO INC (GLTO) stock pay dividends?
GLTO does not pay a dividend.
When does GALECTO INC (GLTO) report earnings?
GALECTO INC (GLTO) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of GALECTO INC (GLTO)?
GALECTO INC (GLTO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.62).
What is the Short Interest ratio of GALECTO INC (GLTO) stock?
The outstanding short interest for GALECTO INC (GLTO) is 5.48% of its float. Check the ownership tab for more information on the GLTO short interest.
GLTO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GLTO. When comparing the yearly performance of all stocks, GLTO is a bad performer in the overall market: 96.94% of all stocks are doing better.
GLTO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLTO. GLTO has a great financial health rating, but its profitability evaluates not so good.
GLTO Financial Highlights
Over the last trailing twelve months GLTO reported a non-GAAP Earnings per Share(EPS) of -17.62. The EPS increased by 51.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.14% | ||
| ROE | -135.42% | ||
| Debt/Equity | 0 |
GLTO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GLTO. The Buy consensus is the average rating of analysts ratings from 8 analysts.